Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
Inventors
Kelson, Itzhak • Keisari, Yona • Gat, Amnon • Den, Robert • Magen, Ofer • Domankevich, Vered • Arazi, Lior • Cooks, Tomer • Heger, Guy • Duman{hacek over (c)}ić, Mirta • Luz, Ishai • Vatarescu, Maayan Hedva
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12042668-B2
Publication Date
2024-07-23
Expiration Date
Abstract
A method for treating a tumor, comprising identifying a tumor as a squamous cell carcinoma tumor and implanting in the tumor identified as a squamous cell carcinoma tumor at least one diffusing alpha-emitter radiation therapy (DaRT) source (21) with a suitable radon release rate and for a given duration, such that the source (21) provides during the given duration a cumulated activity of released radon between 3.7 Mega becquerel (MBq) hour and 8.6 MBq hour, per centimeter length.
Core Innovation
The described technology concerns tumor-specific diffusing alpha-emitter radiation therapy treatment planning for squamous cell carcinoma. It identifies a squamous cell carcinoma tumor and selects source spacing, treatment duration, and radon release rate to provide a target cumulated activity of released radon. The description identifies a preferred source spacing of 4.5 mm and a radon release rate of 0.8–1.85 μci/cm, corresponding to about 3.7–8.6 MBq·h/cm for long-term treatment.
Tumor diffusion measurements, dose modeling, and comparison of measured and modeled radiation-activity profiles support tailoring activity to achieve a safety factor while limiting systemic radiation exposure. Effective diffusion length varies across squamous cell carcinoma samples with a near-zero fitted relationship to tumor weight. The disclosure further addresses diffusing alpha-emitter radiation therapy source arrays, radiotherapy planning systems, and sterile source kits.
Claims Coverage
The independent claims cover a method for treating a squamous cell carcinoma tumor and a source kit for use in the treatment, defining two inventive features.
Dart treatment method for squamous cell carcinoma
The method identifies a tumor as a squamous cell carcinoma tumor and implants an array of DaRT sources with a defined radon release rate and duration to provide a cumulated activity of released radon between 3.8 and 7 MBq·h per centimeter length, with adjacent sources separated by not more than 4 millimeters.
Dart source kit for squamous cell carcinoma
The kit comprises DaRT sources having a support of at least 1 millimeter in length with radium-224 atoms coupled to the support, limits on radium-224 atoms and daughter radionuclides leaving the support, a radon release rate of 0.8–1.6 μci per centimeter length, and configuration for implantation throughout the tumor with source spacing of not more than 4 millimeters.
The claims cover both a treatment method defining radon activity and source spacing, and a source kit specifying radionuclide-release characteristics, radon release rate, and implantation spacing.
Stated Advantages
Tailoring activity to achieve a safety factor while limiting systemic radiation exposure.
Documented Applications
Treatment of a squamous cell carcinoma tumor using diffusing alpha-emitter radiation therapy (DaRT) sources.
Interested in licensing this patent?